--- canonical_name: TUDCA alternate_names: Tauroursodeoxycholic Acid, Tauro-Ursodeoxycholic Acid, Tauroursodeoxycholate, Taurursodiol, Ursodoxicoltaurine, Sodium Tauroursodeoxycholate canonical_topic: TUDCA for Health & Longevity short_topic_lc: tudca creation_date: 2026-0917-1846 creator_ai_fullname: Opus 5 ep_keywords: Bile Acids, Chemical Chaperones --- # TUDCA for Health & Longevity

Evidence Review created on 09/17/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Tauroursodeoxycholic Acid, Tauro-Ursodeoxycholic Acid, Tauroursodeoxycholate, Taurursodiol, Ursodoxicoltaurine, Sodium Tauroursodeoxycholate ## Motivation Tauroursodeoxycholic acid (TUDCA) is a water-soluble bile acid the body makes in small amounts from ursodeoxycholic acid and taurine. Bile acids were long treated as little more than detergents for digesting fat, but this one behaves like a molecular helper: it steadies proteins as cells fold them and holds back the self-destruct programme stressed cells otherwise run. That property is why it is discussed well beyond digestion, most often in connection with liver health and blood sugar control. Dried bear bile, in which it is the dominant bile acid, appears in Chinese medical writing more than a thousand years old. A manufactured version has been licensed in Italy and several other European countries since the early 1990s for gallstones and for chronic liver conditions in which bile flow is impaired, and it is sold in the United States as a dietary supplement. Laboratory work suggesting it might protect nerve cells widened interest sharply. This review examines what is known about tauroursodeoxycholic acid as a longevity intervention: how it is thought to work, what human studies have and have not shown, where the evidence is contested, what harms are recorded, and how it has been dosed, sourced and monitored. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists high-level overviews of tauroursodeoxycholic acid that are useful entry points into the topic. * [Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases](https://pubmed.ncbi.nlm.nih.gov/35659112/) - Khalaf et al., 2022 The broadest modern synthesis of the compound's cell-protective biology, walking through the protein-folding and anti-cell-death mechanisms and then mapping them onto each neurodegenerative disease in turn. * [The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases](https://pubmed.ncbi.nlm.nih.gov/24891994/) - Vang et al., 2014 The best single orientation to why a bile acid is discussed outside hepatology at all, covering metabolic, cardiac, retinal and neurological applications in one readable narrative. * [Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease](https://pubmed.ncbi.nlm.nih.gov/31700226/) - Daruich et al., 2019 A focused account of the eye evidence, including how the compound reaches retinal tissue and why the photoreceptor findings have not yet been tested in people. * [Application of Tauroursodeoxycholic Acid for Treatment of Neurological and Non-neurological Diseases: Is There a Potential for Treating Traumatic Brain Injury?](https://pubmed.ncbi.nlm.nih.gov/26759227/) - Gronbeck et al., 2016 A critical survey that sets out dosing, tolerability and blood-brain-barrier considerations across the conditions studied, and is unusually explicit about where the evidence stops. * [Tauroursodeoxycholic acid: a bile acid that may be used for the prevention and treatment of Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/38440398/) - Song et al., 2024 A current, open-access account of the memory and amyloid literature that also summarises absorption, distribution and the practical obstacles to reaching the brain. Note on priority sources: no content from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io could be found on this compound; all six platforms were searched directly and none returned an item that discusses it by name. The five items above are the qualifying high-level overviews that were found; the list was not padded with marginally relevant material. ## Grokipedia * [Tauroursodeoxycholic acid](https://grokipedia.com/page/Tauroursodeoxycholic_acid) A dense reference entry covering chemistry, endogenous formation, the bear-bile background, licensed indications in Europe, and the neurodegeneration trial record, with inline sourcing throughout. ## Examine * [TUDCA](https://examine.com/supplements/tudca/) Examine's dedicated page, valuable for its per-condition evidence grades, its tabulated dose ranges by indication, and a safety section that separates documented adverse events from theoretical interactions. ## ConsumerLab * [TUDCA Benefits & Safety](https://www.consumerlab.com/answers/is-tudca-beneficial-and-safe/tudca/) ConsumerLab's dedicated page on the compound, useful for its cost-per-dose comparisons across retail brands and its short, sceptical appraisals of the fatty-liver, reflux and amyloidosis (abnormal protein deposits in organs) claims. ## Systematic Reviews This section lists the systematic reviews and meta-analyses bearing most directly on tauroursodeoxycholic acid, covering both its claimed effects and its safety record. * [Efficacy of Sodium Phenylbutyrate-Taurursodiol in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/42301686/) - Jomaa et al., 2026 Pooled two randomised trials (801 participants) of the phenylbutyrate–taurursodiol co-formulation; no significant survival or functional benefit, certainty of evidence rated very low. * [Bile acids for viral hepatitis](https://pubmed.ncbi.nlm.nih.gov/12804455/) - Chen et al., 2003 Cochrane review of 27 randomised bile-acid trials, four using TUDCA; liver enzymes improved in hepatitis B and C, but viral and survival outcomes did not. * [Bile acids for liver-transplanted patients](https://pubmed.ncbi.nlm.nih.gov/16034975/) - Chen & Gluud, 2005 Cochrane review of seven randomised trials in liver-transplant recipients, one using tauroursodeoxycholic acid; no benefit on mortality or rejection, and bile acids were well tolerated. * [Neuroprotective Effect of Tauroursodeoxycholic Acid (TUDCA) on In Vitro and In Vivo Models of Retinal Disorders: A Systematic Review](https://pubmed.ncbi.nlm.nih.gov/37691227/) - Li et al., 2024 Synthesises 24 laboratory and animal studies in retinal disease; consistently protective, but no clinical trials support the effect in people. * [TUDCA and 4-PBA in Preclinical Models of Beta-Cell Secretory Failure: A Systematic Review and Bayesian Meta-Analysis](https://pubmed.ncbi.nlm.nih.gov/42653271/) - Ramos-Jiménez et al., 2026 Bayesian pooling of four preclinical studies; tauroursodeoxycholic acid or phenylbutyrate restored glucose-stimulated insulin secretion 1.85-fold, but no human data were included. ## Mechanism of Action TUDCA is the taurine conjugate of ursodeoxycholic acid (UDCA, a bile acid licensed for impaired bile flow). Three actions dominate. First, it acts as a chemical chaperone. Inside the endoplasmic reticulum (ER, the compartment where cells fold new proteins), misfolded protein triggers the unfolded protein response (UPR, an emergency programme that halts protein synthesis and, if stress persists, kills the cell). TUDCA stabilises folding intermediates and damps the UPR's pro-death arm, reducing signalling through CHOP (a switch protein that executes stress-induced cell death). Recent work adds a direct target: TUDCA binds HSP90 (a chaperone that refolds damaged proteins) and raises its refolding activity ([Liu et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39327392/)). Second, it blocks apoptosis (programmed cell death) at the mitochondrion, preventing the pore-forming step that releases cytochrome c and starts the dismantling of a dying cell. Third, it is water-loving. Enriching the bile pool displaces detergent-like bile acids that injure liver and bile-duct cells ([Invernizzi et al., 1999](https://pubmed.ncbi.nlm.nih.gov/9918905/)). Which action explains the clinical effects is contested: the neurodegeneration programme assumed intracellular chaperoning, whereas hepatology attributes the enzyme changes to displacement of toxic bile acids. Pharmacologically, TUDCA is absorbed in the ileum, recirculates between gut and liver, distributes within that circuit rather than systemically, and clears in faeces. Plasma half-life is a few hours. It is not target-selective: chaperoning acts physicochemically on unstable proteins generally. Metabolism is bacterial deconjugation plus hepatic re-amidation and glucuronidation by UGT1A3 (an enzyme attaching sugar groups to aid excretion), not cytochrome P450 oxidation (the liver's main drug-breakdown route). ## Historical Context & Evolution The compound's first use was not as a molecule at all. Dried bear gallbladder, in which TUDCA is the predominant bile acid, was prescribed in Chinese medicine from roughly the seventh century for jaundice, liver complaints and eye disease. Ursodeoxycholic acid was isolated from bear bile in the early twentieth century and named after the genus *Ursus*; conjugating it with taurine yields TUDCA. Its original clinical purpose was narrow and biliary. Italian hepatology groups in Milan developed it through the 1980s as a better-absorbed alternative to UDCA for dissolving cholesterol gallstones and treating chronic cholestasis (long-standing impaired bile flow), and it was licensed in Italy in 1991. Head-to-head work showed it produced greater biliary enrichment and generated less of the toxic secondary bile acid lithocholic acid than UDCA ([Invernizzi et al., 1999](https://pubmed.ncbi.nlm.nih.gov/9918905/)). The turn toward health optimisation came from cell biology rather than hepatology. Once TUDCA was characterised as a chemical chaperone that relieves endoplasmic reticulum stress, the same compound became a candidate wherever misfolded protein drives disease: insulin resistance, retinal degeneration and motor neuron disease. That reframing produced a metabolic trial in obese adults ([Kars et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20522594/)) and, ultimately, a licensed neurology product that was later withdrawn. The earlier biliary findings were never overturned; they were simply overtaken in visibility, and they remain the most reproducible human results the compound has. ## Expected Benefits Evidence levels below follow the class of evidence behind each item, not the population studied. Several results come from people with established disease; where the effect is likely to differ for a healthy, risk-aware adult optimising healthspan, the annotation says so. Four blood markers recur below: alanine aminotransferase (ALT, a transaminase, meaning an enzyme released by damaged liver cells), aspartate aminotransferase (AST, the second transaminase), alkaline phosphatase (ALP, which rises when bile flow is obstructed) and gamma-glutamyl transferase (GGT, which also rises when bile flow is obstructed). So do three study terms: the randomised controlled trial (RCT, in which participants are allocated to treatment or comparator by chance), the confidence interval (CI, the range within which the true value probably lies) and relative risk (RR, the ratio of event rates between two groups). ### High 🟩 🟩 🟩 #### Improvement of Cholestatic and Hepatocellular Liver Enzymes This is the oldest and most reproducible human effect. As a water-loving bile acid, TUDCA enriches the bile pool and displaces the detergent-like bile acids that injure liver and bile-duct cells, lowering ALT, AST, ALP and GGT. A randomised crossover trial in primary biliary cholangitis (a slow autoimmune bile-duct disease) and a double-blind RCT in cirrhosis both showed the effect, as did pooled bile-acid trials in viral hepatitis. Healthy adults whose enzymes are already in range have far less room to improve. **Magnitude:** In the pooled bile-acid analysis the RR of an abnormal ALT at end of treatment was 0.82, 95% CI 0.76 to 0.90 ([Chen et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12804455/)); in cirrhosis, 750 mg daily for six months significantly reduced ALT, AST and ALP from baseline ([Pan et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23592128/)), and 500 mg daily matched UDCA in primary biliary cholangitis ([Larghi et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9146783/)). ### Medium 🟩 🟩 #### Improved Hepatic and Skeletal-Muscle Insulin Sensitivity Relieving endoplasmic reticulum stress restores insulin signalling in obese rodents, and a single randomised placebo-controlled trial tested that directly in people. Twenty obese adults received 1,750 mg daily for four weeks, with insulin action measured by the hyperinsulinaemic-euglycaemic clamp, the reference method. Liver and muscle sensitivity rose; fat tissue did not respond, and stress markers in muscle and fat biopsies were unchanged, so the mechanism behind the clinical result remains unconfirmed. For metabolically healthy adults the headroom is smaller, and no trial has tested that group. **Magnitude:** Hepatic and skeletal-muscle insulin sensitivity each increased by approximately 30% versus no change on placebo, with parallel increases in the activation of muscle insulin-signalling proteins ([Kars et al., 2010](https://pubmed.ncbi.nlm.nih.gov/20522594/)). #### Preserved Endothelial Function After a Glucose Load A sugar load transiently stiffens and impairs the artery lining in healthy people, an effect attributed to endoplasmic reticulum stress in the vessel wall. In a single-blind randomised crossover trial, twelve healthy young adults took one 1,500 mg dose or placebo before an oral glucose challenge, with flow-mediated dilation (FMD, an ultrasound measure of how well an artery widens) assessed before and after. The protection was complete, but the trial was small, acute and single-dose, and glucose and insulin responses themselves were unaffected. **Magnitude:** FMD fell 32% at 60 minutes and 28% at 120 minutes after glucose on placebo, versus −4% and +0.3% on TUDCA, which were not different from baseline ([Walsh et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27503949/)). ### Low 🟩 #### Slowed Functional Decline in Amyotrophic Lateral Sclerosis ⚠️ Conflicted Two positive randomised trials — one of TUDCA alone, one of a phenylbutyrate co-formulation developed by Amylyx Pharmaceuticals, which funded and co-designed it — were each followed by a negative phase 3 trial and, for the co-formulation, voluntary market withdrawal. Net reading: the early functional signal has not survived adequately powered replication. **Magnitude:** Responder rate 87% versus 43% on placebo ([Elia et al., 2016](https://pubmed.ncbi.nlm.nih.gov/25664595/)); functional decline −1.24 versus −1.66 points per month ([Paganoni et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32877582/)). #### Reduced Disease Activity in Ulcerative Colitis Six weeks of 1.75–2 g daily in an uncontrolled, open-label trial of thirteen patients reduced clinical, endoscopic and histological disease activity and lowered mucosal stress markers. With no control group and a very small sample, the result is preliminary. **Magnitude:** Mean total Mayo disease-activity score fell from 9 to 4.5 over six weeks ([Lamm et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40236400/)). #### Reduced Biliary Cholesterol Saturation and Gallstone Dissolution The original licensed indication. A water-loving bile acid lowers the cholesterol saturation of bile, the state in which stones form and can redissolve. Human evidence is thin and mixed: a randomised trial in gallstone patients shifted bile composition but did no better than probiotics, and dissolution needs small, non-calcified stones. **Magnitude:** Serum and biliary bile acid, cholesterol and phospholipid all fell significantly on treatment, but no stone-dissolution rate was reported and the literature gives no outcome figure for dissolution with this compound ([Gao et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36353477/)). ### Speculative 🟨 #### Extension of Lifespan and Healthspan In nematodes TUDCA extended lifespan; in old mice it improved exercise capacity and cognition via HSP90 refolding. The basis is animal work only; no human longevity outcome exists ([Liu et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39327392/)). #### Retinal Neuroprotection Across 24 laboratory and animal studies the compound slowed photoreceptor loss in inherited and diabetic retinal disease models. The basis is preclinical only; no clinical trial has tested vision ([Li et al., 2024](https://pubmed.ncbi.nlm.nih.gov/37691227/)). #### Neuroprotection in Alzheimer's and Parkinson's Models Across cell and rodent models the compound lowered amyloid burden, protected dopamine-producing neurons and improved memory tasks. The basis is preclinical only; no human trial has tested either disease ([Khalaf et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35659112/)). #### Immune Modulation in Progressive Multiple Sclerosis A placebo-controlled trial of 2 g daily for sixteen weeks shifted circulating T-cell subsets and gut bacteria but changed no clinical outcome. These are unvalidated biomarkers, not endpoints ([Ladakis et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39447576/)). ## Benefit-Modifying Factors * **Ileal bile-acid transporter variants:** Uptake depends on the ileal transporter encoded by *SLC10A2* (the gene for the protein that reclaims bile acids from the gut). Reduced-function variants lower absorption and blunt biliary enrichment, the step every downstream effect depends on. * **Glucuronidation genotype:** *UGT1A3*, which codes an enzyme that tags bile acids with sugar groups for excretion, varies widely between individuals. Rapid-conjugator genotypes clear the compound faster and are expected to need the upper end of studied doses. * **Baseline liver enzymes:** The enzyme benefit tracks how abnormal the starting values are. Adults with raised alkaline phosphatase, gamma-glutamyl transferase or transaminases show the clearest falls; those already in range have little measurable room to move. * **Baseline insulin resistance:** The insulin-sensitivity trial recruited obese adults with a mean body mass index of 37. Sensitivity gains in already insulin-sensitive people are unstudied and, on mechanistic grounds, probably smaller. * **Sex differences:** Pooled rodent spinal cord injury data found markedly larger functional gains in females than males ([Wang et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42693838/)). Human trials have not been powered to test sex, and the cholestatic evidence comes from a predominantly female patient population. * **Pre-existing conditions:** Ileal resection, Crohn's disease affecting the ileum, cholecystectomy (gallbladder removal) and biliary obstruction all disrupt bile-acid recirculation and reduce delivered exposure. Advanced cirrhosis additionally impairs hepatic conjugation. * **Age:** Bile-acid synthesis and pool size decline with age, while baseline protein-folding stress rises, which is the stated rationale for studying older adults. Human trials have not enrolled adults over roughly 75, so this remains inference. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 #### Gastrointestinal Side Effects Diarrhoea, nausea, abdominal discomfort and dyspepsia (indigestion) are the adverse events documented across trials, consistent with an increased bile-acid load reaching the colon. They cluster in the first weeks and then subside. Importantly, the two placebo-controlled trials of TUDCA on its own — in motor neuron disease and in progressive multiple sclerosis — found no excess of adverse events over placebo, so the clearest quantified signal comes from the phenylbutyrate co-formulation, in which phenylbutyrate contributes its own gastrointestinal burden. Severity is mild to moderate and reversible on dose reduction. **Magnitude:** In the co-formulation trial, 19% discontinued for adverse events versus 8% on placebo, diarrhoea caused discontinuation in 6% versus 0%, and dose interruption for gastrointestinal events occurred in 9% versus 2% ([Paganoni et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32877582/)); with TUDCA alone, adverse events did not differ from placebo ([Ladakis et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39447576/)). ### Medium 🟥 🟥 #### Elevated Circulating Bile-Acid Concentrations Supplementation measurably raises serum concentrations of several bile acids, which is the intended pharmacology but also the proximate cause of bile-acid-driven itch and the biochemical abnormality that defines cholestasis of pregnancy. A single placebo-controlled trial measured this directly and reported no clinical consequence over sixteen weeks. The concern is therefore theoretical in healthy adults but material in anyone with impaired bile flow, in whom circulating bile acids are already elevated, and it underlies the standard caution against use in pregnancy. **Magnitude:** The treated arm showed significantly increased serum levels of multiple bile acids over sixteen weeks at 2 g daily, with no accompanying clinical or fluid-biomarker change; the literature reports no outcome figure linking this rise to harm ([Ladakis et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39447576/)). ### Low 🟥 #### Harm Signal From High-Dose Bile-Acid Therapy The only randomised evidence that a water-loving bile acid can do net harm comes from high-dose ursodeoxycholic acid in primary sclerosing cholangitis (a scarring disease of the bile ducts): enzymes improved while hard outcomes worsened. The evidence is indirect — different bile acid, far higher dose. **Magnitude:** At 28–30 mg/kg daily the risk of reaching a clinical endpoint was 2.3 times that of placebo, and serious adverse events occurred in 63% versus 37% ([Lindor et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19585548/)). #### Rash and Pruritus (Itching) ⚠️ Conflicted Rash and itching have been reported twice, only in uncontrolled studies; bile-acid-driven itch is a recognised phenomenon, lending plausibility ([Examine, 2024](https://examine.com/supplements/tudca/)). A controlled trial found no rise in itching on TUDCA, unlike the comparator bile acid ([Ma et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27893675/)). Net reading: the uncontrolled reports are not corroborated. **Magnitude:** Pruritus or scratching rose from 1.4% to 10.0% of patients on ursodeoxycholic acid over 24 weeks but did not change on TUDCA ([Ma et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27893675/)). ### Speculative 🟨 #### Hypoglycaemia With Glucose-Lowering Therapy Because the compound improves insulin sensitivity, combining it with insulin or insulin-releasing drugs could lower blood glucose too far. The basis is mechanistic only; no case report or trial records such an event ([Examine, 2024](https://examine.com/supplements/tudca/)). #### Unknown Fetal and Infant Exposure No safety study covers pregnancy or breastfeeding, and reference sources class it among compounds to avoid. Ursodeoxycholic acid is used safely in pregnancy, but that does not transfer; the basis is absence of data. #### Colonic Bile-Acid Load A larger bile-acid flux into the colon underlies laboratory concerns about bile acids promoting epithelial proliferation. The basis is in-vitro and animal work; no human study links supplementation to colonic pathology. ## Risk-Modifying Factors * **Bile salt export pump variants:** Variants in *ABCB11* (the gene for the liver's main bile-acid export pump) impair biliary secretion. Carriers retain bile acids in liver cells, where an added load is more likely to cause injury than benefit. * **Baseline bile acids and bilirubin:** Elevated fasting serum bile acids or bilirubin indicate impaired bile flow. Adding an oral bile acid to that state increases circulating levels further and is the setting in which itch is most likely. * **Sex differences:** Cholestatic itch, gallstone disease and cholestasis of pregnancy are all substantially more common in women, so bile-acid-related adverse events plausibly concentrate there. Trials have not reported sex-stratified adverse-event rates. * **Pre-existing conditions:** Complete biliary obstruction, acute cholecystitis (gallbladder inflammation), calcified gallstones and decompensated cirrhosis all convert a bile-flow-stimulating agent into a hazard. Inflammatory bowel disease of the ileum increases colonic bile-acid spill-over and diarrhoea. * **Age:** Older adults tolerate volume loss from diarrhoea poorly and more often take bile-acid-binding or glucose-lowering drugs. No trial has reported adverse events separately for adults over 75. ## Key Interactions & Contraindications * **Bile acid sequestrants (cholestyramine, colestipol, colesevelam):** Caution. These bind bile acids in the gut and can abolish absorption, removing all effect. Separating administration by at least four hours is the standard mitigation. * **Aluminium-containing antacids and sucralfate (over-the-counter):** Caution. Aluminium salts adsorb bile acids and reduce bioavailability, with loss of efficacy rather than toxicity. Dosing at least two hours apart is used to avoid this. * **Activated charcoal and high-dose soluble fibre (over-the-counter):** Caution. Both are non-specific binders that reduce absorbed dose and therefore efficacy. Separation by two to four hours is the usual approach. * **Insulin and sulfonylureas (drugs that make the pancreas release more insulin, e.g., glipizide, glyburide):** Monitor. Additive insulin sensitisation may produce hypoglycaemia. Closer glucose monitoring, and dose reduction of the glucose-lowering drug if readings fall, are the stated mitigations. * **Ciclosporin:** Monitor. Bile acids increase ciclosporin absorption and can raise blood levels into the toxic range, risking kidney injury. Trough-level measurement after starting or stopping is the mitigation. * **Oestrogens and oral contraceptives:** Caution. These raise biliary cholesterol saturation and counteract gallstone-dissolving effects; no toxicity, but loss of that specific benefit. * **Glucose-lowering supplements (berberine, alpha-lipoic acid, chromium, cinnamon extract):** Monitor. Additive effects on insulin sensitivity and fasting glucose. Staggered introduction and glucose monitoring are the practical mitigations. * **Hepatic-support supplements (silymarin, N-acetylcysteine, choline, glycine):** Additive rather than adverse. No documented interaction; combined use is common and the additive effect is on liver enzymes. * **Glucagon-like peptide-1 receptor agonists (semaglutide, tirzepatide):** Monitor. Additive glucose lowering, and the rapid weight loss these drugs produce independently raises gallstone risk, altering the background against which biliary effects are read. **Populations who should avoid TUDCA:** * Complete biliary obstruction, or a non-functioning gallbladder with cystic-duct blockage * Acute cholecystitis, acute cholangitis or active biliary colic (gallstone pain) * Radio-opaque or calcified gallstones, where dissolution cannot occur * Decompensated cirrhosis, Child-Pugh Class C (the most severe grade of liver failure) * Primary sclerosing cholangitis at doses above 20 mg/kg daily, given the high-dose harm signal * Pregnancy and breastfeeding, on grounds of absent human safety data * Children and adolescents under 18, for whom no dose has been established * Known hypersensitivity to bile acids or to taurine-conjugated compounds ## Risk Mitigation Strategies * **Low starting dose with slow titration:** Protocols commonly begin at 250 mg once daily and increase by 250 mg every 5–7 days toward the target, which limits the early diarrhoea and nausea that drive most discontinuations. * **Split rather than single daily dosing:** Dividing the daily amount into two or three doses of 250–500 mg reduces the peak bile-acid load reaching the colon, the direct cause of osmotic diarrhoea. * **Four-hour separation from binders:** Taking the compound at least four hours from bile acid sequestrants, aluminium antacids, activated charcoal or bulk fibre prevents the binding that would otherwise abolish absorption. * **Dose ceiling of 20 mg/kg daily:** Keeping below roughly 20 mg/kg daily stays well under the 28–30 mg/kg exposure at which high-dose bile-acid therapy produced excess serious adverse events. * **Biliary imaging before use with a gallstone history:** Abdominal ultrasound before starting identifies calcified stones and obstruction, the states in which a bile-flow-stimulating agent can precipitate gallstone pain or gallbladder inflammation. * **Baseline and follow-up liver panel:** Measuring transaminases, alkaline phosphatase, gamma-glutamyl transferase and bilirubin at baseline and at 6–8 weeks detects the paradoxical enzyme rise that signals impaired bile flow rather than benefit. * **Tighter glucose monitoring on insulin or sulfonylureas:** More frequent glucose checks for the first 2–4 weeks catch the additive insulin-sensitising effect before symptomatic hypoglycaemia occurs. * **Discontinuation on rash or itch:** Stopping at the first appearance of pruritus or rash addresses the bile-acid-driven skin reactions reported in uncontrolled studies, which resolve on withdrawal. ## Therapeutic Protocol * **Standard dose range:** Human trials have used 250 mg to 2,000 mg daily. The most common longevity-oriented practice is 500–1,000 mg daily; hepatology used 500–1,500 mg daily and metabolic and neurological trials 1,750–2,000 mg daily. * **Hepatology approach:** The Milan group around Podda, Crosignani and Battezzati established 500–750 mg daily for chronic cholestasis, positioning the compound as a better-absorbed alternative to ursodeoxycholic acid rather than an addition to it. * **Neurology approach:** The Amylyx-developed co-formulation fixed 1 g of taurursodiol with 3 g of sodium phenylbutyrate twice daily, while the European academic trials used 1 g twice daily of the bile acid alone alongside riluzole. * **Metabolic approach:** The insulin-sensitivity work used 1,750 mg daily for four weeks as a single strategy, without titration, and the vascular work used one 1,500 mg dose taken hours before the measurement. * **Best time of day:** Evening or bedtime dosing is conventional in biliary use, since the bile-acid pool is least diluted overnight; metabolic protocols distributed doses across the day with no timing rationale stated. * **Half-life:** Plasma half-life is a few hours, but enterohepatic recycling several times daily sustains biliary enrichment far longer, which is why steady-state enrichment rather than plasma level governs dosing. * **Single versus split dosing:** Split dosing is the norm. Two or three divided doses improve gastrointestinal tolerance and maintain more even biliary enrichment than one large dose. * **Genetic influences on dose:** Reduced-function *SLC10A2* transporter variants and rapid *UGT1A3* conjugator genotypes both lower delivered exposure, arguing for the upper part of the range; no pharmacogenetic dosing algorithm exists. * **Sex-based differences:** No human trial has reported sex-stratified dosing or response. Rodent work showing larger effects in females has not been replicated in people, so identical dosing is used. * **Age-related considerations:** Bile-acid pool size falls with age, which argues for standard rather than reduced doses in older adults; against that, tolerance of diarrhoea is poorer, so slower titration is usual. * **Baseline biomarkers guiding dose:** Elevated alkaline phosphatase or gamma-glutamyl transferase, or a raised fasting insulin, identify those with the most measurable headroom and are used to justify the higher end of the range. * **Pre-existing conditions:** Ileal disease or resection and cholecystectomy reduce absorption and recirculation; in these settings higher doses are used, while advanced cirrhosis calls for lower doses under specialist supervision. ## Discontinuation & Cycling * **Lifelong versus short-term:** In chronic cholestatic disease use is indefinite. Outside that setting, practice is a defined 8–12 week course tied to a biomarker target, since no trial supports open-ended supplementation. * **Withdrawal effects:** None documented. The compound produces no dependence or rebound syndrome; no trial has reported withdrawal symptoms after stopping at any dose tested. * **Loss of effect on stopping:** The biochemical effect is maintenance-dependent. Liver enzymes drift back toward pre-treatment values over weeks to months once biliary enrichment washes out, as seen after ursodeoxycholic acid withdrawal. * **Tapering:** No taper is required and none has been used in trials, which stopped abruptly at the end of the treatment period without incident. A brief step-down is sometimes used simply to observe the biomarker rebound. * **Cycling:** No efficacy tolerance has been demonstrated, so cycling has no evidence base. Where it is practised — typically eight weeks on, four weeks off — the stated rationale is reassessment and cost, not restoring responsiveness. ## Sourcing and Quality * **Synthetic rather than animal origin:** Commercial material is synthesised by conjugating ursodeoxycholic acid with taurine, not extracted from bile. Products marketed as containing bear bile raise both animal-welfare and contamination concerns and are a reason to avoid a supplier. * **Purity specification:** A certificate of analysis showing at least 98% purity by high-performance liquid chromatography, with limits on residual solvents, heavy metals and related bile acids, is the basic quality marker for this compound. * **Third-party testing:** Independent verification through programmes such as NSF, Informed Choice, United States Pharmacopeia or Eurofins confirms identity and dose, which matters because label-claim shortfalls cannot be detected by taste or appearance. * **Formulation:** Capsules are preferred to loose powder. The material is hygroscopic (it absorbs moisture from the air) and intensely bitter, so powder clumps and is hard to measure accurately, producing inconsistent daily exposure. * **Prescription versus supplement grade:** In Italy and China the compound is a licensed pharmaceutical held to pharmacopoeial standards, whereas in the United States it is a dietary supplement. Compounding pharmacies can supply pharmaceutical-grade material where permitted. * **Brand selection:** ConsumerLab has published cost-per-dose comparisons across widely distributed brands such as Nutricost, Double Wood Supplements and BulkSupplements, which is the most useful public basis for comparing retail products. ## Practical Considerations * **Time to effect:** The vascular effect appears within hours of a single dose. Insulin sensitivity changed over four weeks, and liver enzymes typically move within 4–8 weeks, with maximal change by three to six months. * **Common pitfall — confusing it with ursodeoxycholic acid:** The two are distinct compounds with different absorption and different licensed indications. Evidence for one is routinely and wrongly cited as evidence for the other. * **Common pitfall — underdosing:** Retail products are often 250–300 mg once daily, well below the 1,500–1,750 mg used in the metabolic and vascular trials. Expecting trial-level effects from a fraction of the trial dose is the most frequent error. * **Common pitfall — reading enzyme improvement as benefit:** High-dose bile-acid therapy improved liver enzymes while worsening hard outcomes, so a falling enzyme panel is not by itself evidence that the intervention is helping. * **Regulatory status:** A licensed prescription medicine in Italy since 1991 and in China; a dietary supplement in the United States, where disease claims are not permitted. Not prohibited under the 2026 World Anti-Doping Agency list. * **Withdrawn neurology product:** The phenylbutyrate co-formulation was approved in the United States and Canada in 2022 and voluntarily withdrawn in 2024 after its phase 3 trial failed, which is why prescription access in those countries no longer exists. * **Cost and accessibility:** Retail cost is roughly 25 to 60 US dollars monthly at 500–1,000 mg daily. The withdrawn prescription co-formulation listed at about 158,000 US dollars annually, a gap that gives insurers a structural interest in favouring the supplement. ## Interaction with Foundational Habits * **Sleep:** Largely indirect. No trial has measured sleep outcomes. The relevant consideration is timing: bile-acid recirculation is slowest overnight, which is why evening dosing is conventional, but early-treatment diarrhoea can disrupt sleep, so daytime dosing is often used during titration. * **Nutrition:** Direct and two-way. Dietary fat triggers gallbladder emptying and drives the recirculation the compound depends on, so fat-containing meals support exposure. Conversely, bulk fibre, activated charcoal and aluminium antacids bind bile acids, so dosing is separated by several hours. * **Exercise:** Potentiating in animals, unknown in people. Aged mice given the compound improved exercise capacity. Unlike high-dose antioxidants, relieving protein-folding stress has no mechanistic reason to blunt training adaptation, and no human study has examined timing around sessions. * **Stress management:** Indirect only. Protein-folding stress inside cells is unrelated to psychological stress, though sustained cortisol elevation increases hepatic protein-folding load in animal models. No human study has measured cortisol or stress-response outcomes with this compound. ## Monitoring Protocol & Defining Success Before starting, a baseline panel establishes both the headroom available and the safety floor: a full liver panel with transaminases, alkaline phosphatase, gamma-glutamyl transferase, bilirubin and albumin; fasting glucose, fasting insulin and glycated haemoglobin (HbA1c, the three-month average of blood sugar); a lipid panel; and abdominal ultrasound where there is any gallstone history. Success is defined against these starting values, not against population norms, because the compound's documented effects are corrections of abnormal readings rather than improvements on normal ones. Ongoing measurement follows a defined cadence: the liver panel repeats at 6–8 weeks, the metabolic markers at 12 weeks, and both every 3–6 months thereafter, moving to every 6–12 months once values are stable. An enzyme panel that rises rather than falls, or new pruritus, prompts reassessment rather than dose escalation. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | Alanine aminotransferase | 10–26 U/L (men), 9–22 U/L (women) | Primary marker of liver cell injury and the outcome most reliably moved | Conventional laboratories report up to 40–55 U/L as normal, well above the functional target; fasting not required | | Aspartate aminotransferase | 10–26 U/L | Confirms hepatocellular injury and, paired with the above, flags non-liver sources | Conventional upper limit is about 40 U/L; rises after intense exercise, so sampling 48 hours after hard training avoids false elevation | | Alkaline phosphatase | 70–100 U/L | The defining marker of impaired bile flow and the main efficacy endpoint in cholestatic use | Conventional range extends to 130 U/L; bone disease and pregnancy also raise it, so fractionation may be needed | | Gamma-glutamyl transferase | Below 20 U/L | Most sensitive marker of biliary obstruction and of the compound's biliary action | Conventional upper limit is 60–70 U/L, far above optimal; alcohol raises it independently, so abstain 72 hours before testing | | Total bilirubin | 0.4–1.0 mg/dL | Detects impaired bile excretion, the main safety signal for a bile-flow-stimulating agent | Conventional upper limit 1.2 mg/dL; fasting and Gilbert's syndrome (a harmless inherited rise in bilirubin) both raise it, so time-of-day and genotype matter | | Fasting insulin | 2–5 µIU/mL | Tracks the insulin-sensitivity effect, the main metabolic outcome | Conventional ranges extend to 25 µIU/mL and detect almost nothing; requires a 10–12 hour fast and pairs best with fasting glucose | | Glycated haemoglobin | 4.8–5.3% | Confirms whether improved insulin action translates into better glucose control over months | Conventional threshold is below 5.7%; anaemia and altered red-cell lifespan distort it, so a full blood count is a useful companion | | Total serum bile acids | Below 10 µmol/L | The direct safety marker for bile-acid accumulation and the biochemical correlate of itch | Conventional laboratories also use 10 µmol/L, so the two targets coincide; must be drawn fasting, as post-meal levels rise sharply | | High-sensitivity C-reactive protein | Below 0.5 mg/L | General marker of systemic inflammation, the pathway the compound is proposed to damp | Conventional cardiovascular cut-off is below 3 mg/L; any recent infection invalidates the reading, so defer testing two weeks after illness | | Albumin | 4.2–5.0 g/dL | Measures the liver's synthetic capacity, which rose in the cirrhosis trial | Conventional lower limit is 3.5 g/dL; dehydration falsely elevates it, so hydration status is recorded alongside the result | Qualitative markers tracked alongside the laboratory panel: * Stool form and frequency, the earliest indicator of excess colonic bile-acid load * Right upper abdominal discomfort or fullness, which would suggest biliary rather than intestinal intolerance * Skin itch, particularly nocturnal, the characteristic symptom of bile-acid accumulation * Post-meal energy stability and freedom from afternoon sleepiness, a subjective correlate of improved glucose handling * Exercise capacity and recovery, the phenotype improved in aged animals and the most accessible healthspan signal * Cognitive clarity and sustained concentration, similarly improved in aged animals and worth tracking against baseline ## Emerging Research * **Endoplasmic reticulum stress in hypertension:** A phase 1/2 trial ([NCT06025630](https://clinicaltrials.gov/study/NCT06025630), 70 participants, recruiting) tests whether relieving protein-folding stress lowers blood pressure and improves vascular function, extending the single acute vascular finding into a sustained-dosing design with a hard cardiovascular endpoint. * **Metabolic modulation in type 1 diabetes:** A phase 2 trial ([NCT07699380](https://clinicaltrials.gov/study/NCT07699380), 60 participants) evaluates the compound in combination for insulin sensitivity and mitochondrial function, the first attempt to replicate the four-week insulin-sensitivity result in a different metabolic population. * **Diabetic macular oedema:** A phase 2 trial ([NCT07457632](https://clinicaltrials.gov/study/NCT07457632), 69 participants) tests the compound in this condition (fluid swelling at the centre of the retina that blurs vision in diabetes), the first clinical test of the retinal protection seen consistently across 24 preclinical studies. * **Hepatocellular carcinoma immunotherapy:** A phase 2 trial ([NCT07100392](https://clinicaltrials.gov/study/NCT07100392), 141 participants, recruiting) adds the compound to checkpoint blockade (drugs that release the immune system's brakes on tumours) in hepatocellular carcinoma (the commonest primary liver cancer), testing an oncology hypothesis that runs opposite to the anti-cell-death mechanism claimed elsewhere. * **Full reporting of the negative motor neuron trial:** The academic phase 3 trial of the bile acid alone ([NCT03800524](https://clinicaltrials.gov/study/NCT03800524), 337 participants, 18-month treatment) announced topline results in March 2024 showing no effect on functional decline or survival; subgroup and biomarker analyses are still unpublished and will show whether any responder group exists. * **Whether biliary enrichment or chaperoning drives effects:** Distinguishing displacement of toxic bile acids from intracellular protein-folding rescue would determine whether the metabolic and neurological claims rest on the same mechanism as the reproducible liver findings ([Invernizzi et al., 1999](https://pubmed.ncbi.nlm.nih.gov/9918905/)). * **Whether animal healthspan findings transfer:** The nematode lifespan and aged-mouse fitness results ([Liu et al., 2025](https://pubmed.ncbi.nlm.nih.gov/39327392/)) define the central open question for longevity use, and no registered human trial currently measures exercise capacity or cognition in healthy older adults. * **Whether enzyme improvement predicts outcomes:** The high-dose bile-acid trial that improved liver enzymes while worsening survival ([Lindor et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19585548/)) is the strongest reason to doubt biomarker-based claims, and no study has yet tested whether this compound escapes that dissociation. ## Conclusion Tauroursodeoxycholic acid is a water-soluble bile acid, made in small amounts by the body and manufactured for sale, whose distinguishing property is that it steadies proteins as cells fold them and holds back the cellular self-destruct programme. Its most dependable human effect is the oldest one: in people whose liver and bile-flow blood markers are abnormal, those markers improve, and they improve about as much as with the older bile acid it was designed to replace. Single controlled studies also point to better insulin action in people with obesity and to protection of blood vessel lining after a sugar load. Those are real findings, but each rests on one small study. The claims that attracted the most attention have fared worst. A promising signal in motor neuron disease did not survive a larger, properly powered test, and the product built on it was withdrawn from sale. Much of that evidence was funded and shaped by Amylyx Pharmaceuticals, the company selling it, whose withdrawn product carried a price several hundred times that of the same compound sold as a supplement — an asymmetry giving manufacturers and insurers alike an interest in the answer. The lifespan and vision claims rest entirely on animals and cells. Short-term tolerability looks good, with loose stools the usual complaint, and safety beyond about two years is simply unmeasured. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**